دورية أكاديمية
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.
| العنوان: | Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. |
|---|---|
| المؤلفون: | Gordan JD; University of California, San Francisco, San Francisco, CA., Kennedy EB; American Society of Clinical Oncology, Alexandria, VA., Abou-Alfa GK; Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, New York, NY.; Trinity College Dublin Medical School, Dublin, Ireland., Beal E; Karmanos Cancer Center, Detroit, MI., Finn RS; Geffen School of Medicine, UCLA, Los Angeles, CA., Gade TP; Penn Medicine, Philadelphia, PA., Goff L; Vanderbilt Ingram Cancer Center, Nashville, TN., Gupta S; Atlantic Medical Group, Morristown, NJ., Guy J; Sutter Health, San Francisco, CA., Hoang HT; National Cancer Hospital, Hanoi, Vietnam., Iyer R; Roswell Park Comprehensive Cancer Center, Buffalo, NY., Jaiyesimi I; Beaumont Hospital, Royal Oak, MI., Jhawer M; Englewood Hospital, Englewood, NJ., Karippot A; Texas Oncology, Plano, TX., Kaseb AO; MD Anderson Cancer Center, Houston, TX., Kelley RK; University of California, San Francisco, San Francisco, CA., Kortmansky J; Yale Cancer Center, New Haven, CT., Leaf A; VA New York Harbor Healthcare System, Brooklyn, NY., Remak WM; California Hepatitis C Task Force, California Chronic Care Coalition, FAIR Foundation, San Francisco, CA., Sohal DPS; University of Cincinnati, Cincinnati, OH., Taddei TH; Yale University School of Medicine and VA Connecticut Healthcare System, West Haven, CT., Wilson Woods A; Blue Faery: The Adrienne Wilson Liver Cancer Association, Birmingham, AL., Yarchoan M; Johns Hopkins Medicine, Baltimore, MD., Rose MG; Yale Cancer Center and VA Connecticut Healthcare System, West Haven, CT. |
| المصدر: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 May 20; Vol. 42 (15), pp. 1830-1850. Date of Electronic Publication: 2024 Mar 19. |
| نوع المنشور: | Journal Article; Practice Guideline |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2003- : Alexandria, VA : American Society of Clinical Oncology Original Publication: New York, N.Y. : Grune & Stratton, c1983- |
| مواضيع طبية MeSH: | Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/pathology , Liver Neoplasms*/drug therapy , Liver Neoplasms*/pathology, Humans ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Randomized Controlled Trials as Topic |
| مستخلص: | Purpose: To update an evidence-based guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma (HCC). Methods: ASCO convened an Expert Panel to update the 2020 guideline on systemic therapy for HCC. The panel updated the systematic review to include randomized controlled trials (RCTs) published through October 2023 and updated recommendations. Results: Ten new RCTs met the inclusion criteria and were added to the evidence base. Recommendations: Atezolizumab + bevacizumab (atezo + bev) or durvalumab + tremelimumab (durva + treme) may be offered first-line for patients with advanced HCC, Child-Pugh class A liver disease, and Eastern Cooperative Oncology Group performance status 0-1. Where there are contraindications to these therapies, sorafenib, lenvatinib, or durvalumab may be offered first-line. Following first-line treatment with atezo + bev, second-line therapy with a tyrosine kinase inhibitor (TKI), ramucirumab (for patients with alpha-fetoprotein [AFP] ≥400 ng/mL), durva + treme, or nivolumab + ipilimumab (nivo + ipi) may be recommended for appropriate candidates. Following first-line therapy with durva + treme, second-line therapy with a TKI is recommended. Following first-line treatment with sorafenib or lenvatinib, second-line therapy options include cabozantinib, regorafenib for patients who previously tolerated sorafenib, ramucirumab (AFP ≥400 ng/mL), nivo + ipi, or durvalumab; atezo + bev or durva + treme may be considered for patients who did not have access to these therapies in the first-line setting, and do not have contraindications. Pembrolizumab or nivolumab are also options for appropriate patients following sorafenib or lenvatinib. Third-line therapy may be considered in Child-Pugh class A patients with good PS, using one of the agents listed previously that has a nonidentical mechanism of action with previously received therapy. A cautious approach to systemic therapy is recommended for patients with Child-Pugh class B advanced HCC. Further guidance on choosing between options is included within the guideline.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines. |
| تواريخ الأحداث: | Date Created: 20240319 Date Completed: 20240515 Latest Revision: 20240904 |
| رمز التحديث: | 20240905 |
| DOI: | 10.1200/JCO.23.02745 |
| PMID: | 38502889 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1527-7755 |
|---|---|
| DOI: | 10.1200/JCO.23.02745 |